Drug Profile
Influenza A virus H1N1 vaccine - CPL Biologicals
Alternative Names: CadiFlu; H1N1 influenza VLP vaccine - Novavax; H1N1 virus-like particle pandemic influenza vaccine - Novavax; Monovalent influenza A (H1N1 2009) virus like particle (VLP) vaccine - CPL Biologicals; Swine flu vaccine - Novavax; Unadjuvanted 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine - NovavaxLatest Information Update: 13 Apr 2015
Price :
$50
*
At a glance
- Originator Novavax
- Developer CPL Biologicals; Novavax
- Class Influenza A virus H1N1 vaccines; Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype
Most Recent Events
- 31 Dec 2012 CPL Biologicals initiates a phase I trial of its Influenza-A virus H1N1 subtype vaccine in India
- 04 Aug 2011 Final immunogenicity data from a phase II trial in Influenza-A virus H1N1 subtype (Prevention) released by Novavax
- 01 Mar 2011 Novavax receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Influenza virus-like particle vaccines in USA